Latest Breaking News On - Olema pharmaceuticals inc - Page 12 : comparemela.com

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Palazestrant in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile.

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Dec. 04, 2023 Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for.

Top Stocks for December 2023

Top stocks for December 2023 based on value, growth, and performance include AMPY, MAR, and OLMA.

Olema Pharmaceuticals Stock: Advancing On Multiple Fronts (NASDAQ:OLMA)

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with.